‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
Biosimilars Council Chief Sees Improvement In US Market, But Says There Is Further To Go
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is ‘doing better, but we still have improvements to make.’
